NTRA - Natera wins first commercial coverage policies for Signatera cancer test

• Texas-based molecular diagnostic company Natera ( NASDAQ: NTRA ) announced first commercial coverage policies for its cancer screening test, Signatera, on Thursday.
• The company said that Blue Shield of California has decided to cover it for plan members diagnosed with solid tumors for adjuvant, recurrence monitoring, and treatment monitoring effective Mar. 01.
• In addition, Blue Cross and Blue Shield of Louisiana has also introduced a multi-cancer policy covering Signatera for colorectal cancer, bladder cancer, and pan-cancer immunotherapy monitoring, effective Jan. 01.
• “These developments underscore the medical necessity of Signatera to inform critical treatment decisions and detect recurrence earlier,” John Fesko, the chief business officer of Natera ( NTRA ), remarked.
• According to Seeking Alpha contributor Bashar Issa Natera ( NTRA ) is intensifying its efforts to diversify the product portfolio beyond non-invasive prenatal testing.

For further details see: